AXL lipid technology

Lipids are abundant, diverse biomolecules essential for membranes, energy storage, and signaling. They form the basis of liposomes and self-assembling lipid nanoparticles (LNPs), versatile platforms for delivering messenger ribonucleic acids (mRNA) that have the potential to treat a wide range of diseases. Axelyf’s scientific team is creating a digital library of novel chemicals and formulations for mRNA delivery using advanced LNP modeling and innovative surface chemistry.

In August 2024, Axelyf completed acquisition of an integrated lipid library from 76bio. This molecular library of potent delivery compounds for mRNA drugs enables us to pursue best-in-class LNPs for our own product candidates and partner our technology for products of other companies in the future.

A scientific chart displaying different lipid levels in mice, comparing serum protein expressions for various lipid series, with emphasis on the effectiveness of AXL lipid technology for RNA-based therapies. Two bar graphs show protein levels across different experimental groups and tissues (spleen and liver). The figures highlight the potency of lipid nanoparticle formulations exceeding clinical benchmarks and demonstrate robust mRNA translation.

The Axelyf LNP library series (A, B, C, D)  shows highly potent liver delivery and potential for extra-hepatic targeting. Potency compares favorably with industry standard formulation LP-01 (STD) which is commonly used in gene editing clinical trial programs. In partner studies in non-human primates (NHP), AXL lipids achieved higher mRNA translation efficiency at lower doses without signs of toxicity.

Axelyf is equipped to integrate several RNA formats with AXL delivery technology to yield more potent and effective autoimmune therapeutics.

© 2026 Axelyf, Inc.

Comparison table of RNA technologies and Axelyf's unique advantages in each area: Standard mRNA, Circular RNA, Gene Editing, and Gene Writing, with illustrations of RNA structures and descriptions of their features.

© 2026 Axelyf, Inc.

Prodrugs offer a strategic approach to therapeutics by enhancing drug delivery, efficacy, and patient outcomes. They are covalent modifications of drugs with chemical handles that are cleaved in the body, undergoing chemical or enzymatic transformations to release the active form. Designed to improve solubility, bioavailability, and stability, prodrugs address limitations of the parent compound while reducing side effects and increasing therapeutic specificity.

Prodrugs

Diagram illustrating the process of drug absorption, including drug portion, prodrug portion, administration, dissolution, transport, uptake, cleavage, and drug release.

Prodrugs are used in many medical fields including oncology, infectious diseases, psychiatry, and neurology, and examples like L-dopa (Parkinson’s), Tamiflu (influenza), and Prednisone (inflammation) highlight their versatility and commercial success.

© 2026 Axelyf, Inc. Rannis grant supported R&D.

Axelyf’s proprietary prodrug in development (BPH-555) is effective in an arthritis model

A scientific infographic showing the efficacy of BPH-555, a natural compound mix containing astaxanthin and vitamin B3, in reducing paw thickness in a CIA model of collagen-induced arthritis in mice. The graph depicts paw thickness (mm) over days, with different treatments: vehicle, dexamethasone, BPH-555, tofacitinib, and naive mice. The left side lists points about BPH-555, including its drug origin, safety warning, composition, pharmacokinetics, and clinical trial phases. An orange banner at the bottom states the focus on developing a safe, well-tolerated oral drug for RA and other indications, with phase 1 target in 2026.
Text-based infographic comparing different experimental groups: vehicle control with collagen-induced animals treated with placebo, dexamethasone used to treat acute inflammation, Tofa as a tofacitinib and Jak inhibitor for inflammatory and autoimmune conditions, and naive mice not induced with collagen.

© 2026 Axelyf, Inc.

Partnering and collaboration

Axelyf is exploring partnership and collaboration on AXL lipid library and capabilities to deliver best-in-class RNA-LNP technology for medicines. Please get in touch with us at info@axelyfbio.org if you’d like to learn more about our technology.